Opinion

Video

Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.

Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
FDA approval of treprostinil (Yutrepia) -- Image credit: Pakin | stock.adobe.com
May 27th 2025

FDA Approves Treprostinil Inhalation Powder for PAH and PH-ILD

Gillian McGovern, Associate Editor
Pharmacist Involvement in Clinical Research and the FINEARTS-HF Trial
May 20th 2025

Pharmacist Involvement in Clinical Research and the FINEARTS-HF Trial

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Young woman with cardiovascular disease -- Image credit: eddows | stock.adobe.com
May 21st 2025

Study Finds Increased Risk of CVD Among Women With History of Infertilty

Gillian McGovern, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Pregnant woman having her blood pressure taken -- Image credit: didesign | stock.adobe.com
May 12th 2025

Children Born to Mothers With Cardiometabolic Issues Before or During Pregnancy Face Increased Risk of Childhood, Adolescent Hypertension

Gillian McGovern, Associate Editor
Wooden block letters spelling shingles vaccine | Image Credit: © zelwanka - stock.adobe.com
May 9th 2025

Live Zoster Vaccine May Reduce Risk of Cardiovascular Events by 23%, Study Finds

Alexandra Gerlach, Associate Editor